Lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Primary analysis from the phase 2 PILOT study. Sehgal, A., Hoda, D., Riedell, P. A., Ghosh, N., Hamadani, M., Hildebrandt, G., Godwin, J. E., Reagan, P., Wagner-Johnston, N. D., Essell, J., Nath, R., Solomon, S. R., Champion, R., Licitra, E., Fanning, S., Gupta, N. K., Dubowy, R. L., D'Andrea, A., Wang, L., Gordon, L. I. LIPPINCOTT WILLIAMS & WILKINS. 2022

View details for Web of Science ID 000863680301963